Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 200 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infections, Human Immunodeficiency Virus and Herpesviridae Clear all

Conditions: Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Interferon alfa-2b, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 12
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 7 more

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: GSK1349572, Efavirenz; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV, Herpes Simplex Infections
Interventions: MB66, Placebo Film; Drug
Lead sponsor: KBio Inc; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • Menlo Park, California • San Diego, California + 15 more

Conditions: Lymphoma, Primary Effusion
Interventions: Daratumumab SC; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukoplakia, Hairy, HIV Infections
Interventions: Acyclovir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Herpes Simplex, HIV Infections
Interventions: Crofelemer, Acyclovir; Drug
Lead sponsor: Shaman Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 32
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Roche Global Development; Other
Eligibility: 3 Months to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 3 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Roche Global Development; Other
Eligibility: 13 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
Interventions: Bevacizumab; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma
Interventions: Regimen A, Regimen B; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 8
States / cities: Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell Neoplasm
Interventions: Vincristine, Prednisone, Doxorubicin, Etoposide, Pomalidomide, Cyclophosphamide, Rituximab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Cidofovir, Probenecid; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Mitoxantrone hydrochloride; Drug
Lead sponsor: Lederle Laboratories; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Doxorubicin hydrochloride (liposomal); Drug
Lead sponsor: Sequus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Menlo Park, California

Conditions: HIV, HIV Infections
Interventions: T-cell lymphocyte responses; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: SU5416; Drug
Lead sponsor: SUGEN; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • New York, New York

Conditions: Herpes Simplex, HIV Infections
Interventions: Cidofovir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 13 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more

Conditions: Herpes Simplex, HIV Infections
Interventions: Vidarabine, Acyclovir, Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: IM862; Drug
Lead sponsor: Cytran; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Fiacitabine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 4
States / cities: Birmingham, Alabama • San Diego, California • Bethesda, Maryland + 1 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years to 65 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 7 more

Search by objective public record fields.

Comparative Autoantibody and Immunologic Cell Marker Study

The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma

GSK1349572 Drug Interaction Study With Efavirenz

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV

A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV Therapy

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

An Open Label Evaluation of the Safety and Pharmacokinetics of Ganciclovir in Children

A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

A Study of Chemotherapy Plus Azidothymidine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

An Open-Label Study of the Safety and Efficacy of Cidofovir for the Treatment of Relapsing Cytomegalovirus Retinitis in Patients With AIDS

Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma

Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.

T-cell Responses to Concurrent HIV and Herpesvirus Infections

Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure